Press Releases

CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), and Wacker Chemie AG announced today that they had signed a contract for the manufacturing of CureVac’s COVID-19 vaccine candidate CVnCoV.

The Munich-based chemical com¬pany WACKER is to begin construction on a new production line for silane-terminated polymers at its site in Nünchritz, Germany, this year.

In Q3 2020, Wacker Chemie AG posted substantial sales and EBITDA growth versus a quarter ago but did not match its year-earlier figures.

A special honor has been bestowed upon researchers from the WACKER Group and from the WACKER Institute for Silicon Chemistry at the Technical University of Munich, Germany.

Wacker Chemie AG is moving forward with “Shape the Future,” its efficiency program initiated last November.